HDL对支架生物相容性的影响以及PCI术后HDL输注治疗的潜在价值

Impact of HDL on stent biocompatibility and the potential value of HDL infusion therapy after PCI

尽管介入技术与支架设计不断进步,但是支架生物相容性方面的问题仍然存在,包括支架内新生动脉粥样硬化和再内皮化延迟,这些问题会导致支架内再狭窄(ISR)和支架内血栓形成(ST)。高密度脂蛋白(HDL)是一种重要的抗动脉粥样硬化因子,对动脉粥样硬化性心血管疾病(ASCVD)的患者具有保护作用。它能够维护血管内皮正常功能、保护内皮完整性、促进再内皮化、抑制炎症反应和血小板活化,对改善经皮冠状动脉介入术(PCI)术后支架生物相容性有一定的作用。本文就HDL对ASCVD患者PCI术后支架生物相容性的影响进行综述,并探讨HDL输注治疗的新应用方向。

Even the interventional techniques and stent design continue to improve, unresolved problems about stent biocompatibility persist, including neoatherosclerosis and delayed re-endothelialization, which cause in-stent restenosis(ISR) and stent thrombosis(ST). High-density lipoprotein(HDL) is widely recognized as an essential anti-atherogenic factor that plays a protective role against atherosclerotic cardiovascular disease(ASCVD). It can maintenance of vascular endothelial function, protection of endothelial integrity, enhancement of re-endothelialization, reduction of inflammation and platelet activation, playing a certain role in improvement of stent biocompatibility after percutaneous coronary intervention(PCI). The article is to review the effect of HDL on stent biocompatibility in ASCVD patients following PCI and discuss a novel therapeutic direction of HDL infusion therapy.